Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know

Impact · against what's priced in

The article provides no new catalysts for Vertex Pharmaceuticals, as the projected revenue and earnings for the upcoming quarter are consistent with current market expectations and previous guidance.

VRTX+0.00

Already priced in

The price assumes

The raised full-year 2026 revenue guidance of $13.1 billion to $13.2 billion.

The forecasted annual revenue of $13.22 billion aligns almost exactly with the guidance the market has already priced in.